Skip to Main Content
Hematology
YSM Home

INFORMATION FOR

Amer Zeidan, MBBS

Associate Professor of Internal Medicine (Hematology)
DownloadHi-Res Photo

Additional Titles

Chief, Hematologic Malignancies

Director, Early Therapeutics Research, Hematology

Leader, Clinical Research Team for Leukemias and Myeloid Malignancies, Yale Cancer Center

Chair, Protocol Review Committee (PRC) I, Yale Cancer Center

Assistant Medical Director, Clinical Trials Office (CTO), Yale Cancer Center

Director, Hematology Research Seminar Series, Hematology

Member, Executive Committee, Yale Cancer Center

Member, Clinical Trials Advisory Committee (CTAC), Yale Cancer Center

About

Titles

Associate Professor of Internal Medicine (Hematology)

Chief, Hematologic Malignancies; Director, Early Therapeutics Research, Hematology; Leader, Clinical Research Team for Leukemias and Myeloid Malignancies, Yale Cancer Center; Chair, Protocol Review Committee (PRC) I, Yale Cancer Center; Assistant Medical Director, Clinical Trials Office (CTO), Yale Cancer Center; Director, Hematology Research Seminar Series, Hematology; Member, Executive Committee, Yale Cancer Center; Member, Clinical Trials Advisory Committee (CTAC), Yale Cancer Center

Biography

Amer Zeidan, MBBS, MHS @Dr_AmerZeidan is an Associate Professor of Medicine (Hematology) at Yale University. He is also the medical director of Hematology Early Therapeutics Research, the leader of the Myeloid malignancies Clinical Research Team (CRT), and the director of Continuing Medical Education (CME) at the Hematology division at Yale Cancer Center. Dr. Zeidan completed a hematology/oncology fellowship and a clinical research fellowship in myelodysplastic syndromes (MDS) at Johns Hopkins University where he also earned a Master of Health Science (MHS) degree in Clinical Investigation. Dr. Zeidan specializes in the management of myeloid malignancies especially MDS and acute myeloid leukemia (AML).

The focus of Dr. Zeidan’s clinical/translational research is the development of novel therapies for myeloid malignancies, with a special focus on targeted therapies and immunotherapy-based approaches. Dr. Zeidan is also active in health outcomes and comparative effectiveness research for blood cancers and their therapies. Dr. Zeidan has and continues to serve as the principal investigator of many investigator-initiated, cooperative group and industry sponsored clinical trials for myeloid malignancies.

Dr. Zeidan also chairs or serves on the steering committees of several large clinical trials of myeloid malignancies. He has served as the vice chair of the Yale Cancer Center Data and Safety Monitoring Committee (YCC DSMC) and currently serves in the independent data and safety monitoring committees of multiple clinical trials. Dr. Zeidan is a member of the MyeloMATCH Precision medicine initiative of the National Cancer Institute (NCI) for both MDS and AML and is very active within the Cancer Therapy Evaluation Program (CTEP) and Early Therapy Clinical Trial Network (ETCTN) in working on early phase clinical trials of novel therapies for myeloid malignancies.

Dr. Zeidan has presented his research in many meetings and has been an invited speaker nationally and internationally. He regularly reviews abstracts for the American Society of Hematology (ASH) annual meetings and chairs meeting sessions. He has been presented on MDS in the ASH Annual highlights meetings in USA and Asia-Pacific as well as the ASH Meeting on Hematologic Malignancies. He is also active within the International Working Group (IWG) of MDS and has previously served on the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines panel for MDS.

Dr. Zeidan has received several prestigious awards including the Leukemia and Lymphoma Society Scholar in Clinical Research award, the National Cancer Institute Cancer Clinical Investigator Team Leadership award, the AAMDSIF/Evan’s Foundation-MDS Clinical Research Consortium Fellowship award, the Tito Bastianello Young Investigator Award, the ASCO Young Investigator Award, and multiple other achievement awards. Dr. Zeidan also serves on the editorial board and is a reviewer of several important hematology and oncology journals. He is an author on more than 260 peer-reviewed publications and book chapters.

Appointments

  • Hematology

    Associate Professor on Term
    Primary
    Hematology

Other Departments & Organizations

Education & Training

MHS
Johns Hopkins University (2014)
Fellowship
Johns Hopkins Hospital (2013)
Internship
Rochester General Hospital (2010)
MBBS
University of Jordan (2001)

Research

Overview

The focus of my clinical/translational research is the development of novel therapies for MDS, AML, and other hematologic malignancies. Dr. Zeidan is the principal investigator on several clinical trials in MDS, AML and other hematologic malignancies. Dr. Zeidan especially focuses on the use of immunotherapies (drugs that stimulate the patient's own immune system) including the immune checkpoint inhibitors to fight blood cancers.

Clinical research; Novel therapies

Medical Subject Headings (MeSH)

Hematologic Neoplasms; Translational Research, Biomedical

Research at a Glance

Yale Co-Authors

Frequent collaborators of Amer Zeidan's published research.

Publications

2024

See All Publications

Clinical Trials

Current Trials

Academic Achievements & Community Involvement

  • activity

    Developmental Therapeutics Research Program, Yale University

    CommitteesMember
  • activity

    Cancer Outcomes, Public Policy, and Effectiveness Research Center (COPPER), Yale University

    CommitteesMember
  • activity

    Yale Affiliated Hospital Program

    CommitteesLecturer
  • activity

    Yale School of Medicine Internal Medicine Residency Program

    CommitteesInterviewer
  • activity

    Blood Reviews

    Journal ServiceEditorial Board Member
See All Achievements

Clinical Care

Overview

Amer Zeidan, MBBS (a medical degree awarded in several countries outside the U.S.), MHS, is a hematologist who specializes in treating and researching myeloid malignancies.

Myeloid malignancies occur when healthy blood cells throughout the body and in bone marrow do not mature normally and instead replicate, proliferate, or transform in other ways. Dr. Zeidan’s research and clinical care focus on targeting therapies to a patient’s diagnosis and working with their own immune system to counter the malignancies.

At Yale Cancer Center, Dr. Zeidan is the medical director of Hematology Early Therapeutics Research, leader of the Disease Aligned Research Team (DART) for Leukemia and Myeloid Malignancies, and the assistant director of the Clinical Trials Office for hematology.

His research efforts focus on finding new, active, and safe therapies for blood cancers through clinical trials. He also explores why certain standard therapies have not been as effective in practice as they have been in clinical trials, and how the performance of these therapies can be improved in the clinic.

Dr. Zeidan has received many awards, including the Leukemia and Lymphoma Society Scholar in Clinical Research award and the National Cancer Institute Cancer Clinical Investigator Team Leadership award. He serves on the editorial boards of several key hematology and oncology publications, and is the author of more than 260 peer-reviewed studies and chapters of books.

Clinical Specialties

Hematologic Oncology; Hematology

Fact Sheets

See All Fact Sheets On Yale Medicine

Board Certifications

  • Hematology (Internal Medicine)

    Certification Organization
    AB of Internal Medicine
    Latest Certification Date
    2019
    Original Certification Date
    2013

Yale Medicine News

See All News On Yale Medicine

Are You a Patient?

View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.

View Doctor Profile

Get In Touch

Contacts

Appointment Number
Clinic Fax Number

Administrative Support

Locations

  • 37 College Street

    Academic Office

    Fl 1, Rm 101

    New Haven, CT 06510

    Get Directions

  • Patient Care Locations

    Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.

    See Patient Care Locations